Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

ncing, we have raised the necessary funds to build on the pioneering research and foundational intellectual property of our scientific founders for human cell reprogramming and to enable the commercialization of our pharmaceutical grade iPSC technology."

About OVP Venture Partners

For 26 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVP makes early stage investments in cleantech, digital biology and information technology. The firms' record of 52 liquidity events - including 22 IPOs - leads the region. OVP has over $750 million in capital under management and is currently investing its seventh fund. The firm has offices in Seattle, WA and Portland, OR. More information on the partnership is available at www.ovp.com.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit www.fatetherapeutics.
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... TAI,AN, Shandong, China, Sept. ... Bulletin Board: CBPO) ("China Biologic," or the,"Company"), ... in the,People,s Republic of China ("PRC"), operating ... Products Co. Ltd.,("Taibang") and Chongqing Dalin Biologic ...
... CORK, Ireland, September 10 Hovione announced today that,Terry Lambe, ... Ltd. , Hovione acquired earlier this year ... element of the Hovione strategy to become a,leading manufacturer to the ... welcome Terry Lambe to Hovione. We want to build our,Cork site ...
... ROTTERDAM, The Netherlands, September 10 arGEN-X ... human,antibodies using its proprietary SIMPLE Antibody(TM) platform, today,announced the successful ... raised EUR 9.5million ( USD 13.6 million) from a,syndicate of ... largest of its kind in the last 12 months. , ...
Cached Biology Technology:China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 2China Biologic Products to Attend at Susquehanna's Third Annual Beijing Management Summit 3Hovione Appoints Terry Lambe to its Board of Directors 2arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 2arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 3arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 4arGEN-X Raises EUR9.5 Million to put SIMPLE Antibody(TM) Platform to Work 5
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... 2, 2014   Marvin Test Solutions , ... solutions for military, aerospace, and manufacturing organizations, today ... successful TS-900 PXI semiconductor test platform . ... high-end systems to customers at a fraction of ... traditional ATE. "Our semiconductor customers ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... de Physiologie Neurovg tative (CNRS-INRA-Universit Paul C zanne), the ... and from the D partement Lipoprotines et M ... Professor Jean-Pierre Miolan, Dr Jean-Pierre Niel, Directeur de Recherche ... Dr Abel Hiol Ma tre de confrence and ...
... international research team, including biologists from NOAA Fisheries Service, ... had failed to find a single Yangtze River dolphin, ... scientists fear the marine mammal is now extinct due ... the first cetacean to vanish as result of human ...
... Springer, one of the worlds leading STM publishers, will ... publication of the EUCC the Coastal Union. ... to Springers other journals in coastal science, the International ... The first issue of the relaunched JCCO, with ...
Cached Biology News:Scientists fear rare dolphin driven to extinction by human activities 2Springer will publish Journal of Coastal Conservation 2
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... Anti-NY-ESO-1, clone E978 ... NM_001327 Immunogen : ... Formulation: mouse ascites with ... Assurance: routinely evaluated by ...
... Opsin 1 ( Abpromise for all tested ... YEDSTHASIFTYT, corresponding to amino acids 14/26 of Mouse ... to amino acids 18/30 of tiger red cones ... Entrez Gene ID: 5956 ...
Biology Products: